Latest News and Press Releases

Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder

Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.

Optimi Health provides corporate update.

Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export

Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.

Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company’s Precursor Licence.

Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.

Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.

Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.